Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Lantheus stock on January 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 2/3/2025.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 1/31/2025.
• Purchased $50,001 – $100,000 in shares of Hawaiian Electric Industries (NYSE:HE) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of Agios Pharmaceuticals (NASDAQ:AGIO) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of SpringWorks Therapeutics (NASDAQ:SWTX) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Paragon 28 (NYSE:FNA) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of U.S. Physical Therapy (NYSE:USPH) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 1/29/2025.

Lantheus Stock Up 0.2 %

Shares of LNTH stock opened at $82.10 on Thursday. The firm has a 50 day moving average price of $91.76 and a two-hundred day moving average price of $98.13. The company has a market capitalization of $5.71 billion, a PE ratio of 13.66 and a beta of 0.44. Lantheus Holdings, Inc. has a 12-month low of $54.69 and a 12-month high of $126.89.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on LNTH shares. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $131.86.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC bought a new position in Lantheus in the third quarter valued at approximately $1,066,000. Massachusetts Financial Services Co. MA bought a new position in Lantheus in the third quarter valued at approximately $25,955,000. Van ECK Associates Corp increased its stake in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Empirical Asset Management LLC bought a new position in Lantheus in the fourth quarter valued at approximately $323,000. 99.06% of the stock is owned by institutional investors.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.